Contact UsOnline ShoppingNew ProductsUse ConditionsPrivacyResearch

Nutriteck Nutritional Supplements GTF Chromium Supplement

Provides Diabetics-2 support for healthy glucose metabolism

Whey Protein Isolates MoleculesIngredients: Organic chromium enriched yeast,  with cinnamon bark extract

                                                                       Research Microscope Dietary Supplement Information

Medicinal Ingredient : Chromium:................ 150 mcg/dose

Health Canada - Our Product License Number NPN : 80026711

Packaging: 225 gram Economical Bulk: Scoop Included Price: $27.20

Note: Nutritecks products are fine grind concentrated ready to use powders, which may be mixed or added to water and most of your regular non alcoholic beverages or simply sprinkled on your foods (like sprinkling spices), or may even be packaged in standard pill and capsule serving methods without compromising product effectiveness or quality.

Please Note: When calculating your costs of similar products in capsule or pill form which are normally packaged in Example: 4 x 250 mg = 1 gram or 1000 mg. Our 225 gram container has the equivalent of 1000 x 225 mg pills or capsules which results in very considerable savings of from 50 to 70% of the cost in many cases of pill and capsule packaging. 



 Secure On Line SSL Shopping Click Here ->

References reviewed

Anderson MA, Petersson Grawé KV, Karlsson OM, Abramsson-Zetterberg LAG, Hellman BE. 2007. Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro. Food and Chemical Toxicology 45:1097-1106. Anderson RA, Bryden NA, Polansky MM, Gautschi K.1996. Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. The Journal of Trace Elements in Experimental Medicine 9(1):11-25.

Anderson RA, Bryden NA, Polansky MM. 1997. Lack of toxicity of chromium chloride and chromium picolinate in rats. Journal of the American College of Nutrition 16(3):273-279.

Anderson RA, Polansky MM, Bryden NA, Patterson KY, Veillon C, Glinsmann WH. 1983. Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. The Journal of Nutrition 113(2):276-281.

Anderson RA. 1998. Chromium, Glucose Intolerance and Diabetes. Review Article. Journal of the American College of Nutrition 17(6): 548-555. ATSDR 2008: Agency for Toxic Substances and Disease Registry. 2008. Draft Toxicological Profile for Chromium. U.S Department of Health and Human Services. [Accessed 2009 December 4]. Available from: http://www.atsdr.cdc.gov/toxprofiles/tp7.html Bagchi D, Bagchi M, Balmoori J, Ye X, Stohs SJ. 1997.

Comparative induction of oxidative stress in cultured J774A.1 macrophage cells by chromium picolinate and chromium nicotinate. Research Communications in Molecular Pathology and Pharmacology 97(3):335-346. Bailey MM, Boohaker JG, Jernigan PL, Townsend MB, Sturdivant J, Rasco JF, Vincent JB, Hood RD. 2008. Effects of Pre- and Postnatal Exposure to Chromium Picolinate or Picolinic Acid on Neurological Development in CD-1 Mice.

 Biological Trace Element Research 124:70-82. Bailey MM, Boohaker JG, Sawyer RD, Behling JE, Rasco JF, Jernigan JJ, Hood RD, Vincent JB. 2006. Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring. Birth Defects Research. Part B. Developmental and Reproductive Toxicology 77(3):244-249. Bailey MM, Sturdivant J, Jernigant PL, Townsend MB, Bushman J, Ankareddi I, Rasco JF, Hood RD, Vincent JB. 2008.

 Original Article: Comparison of the Potential for Developmental Toxicity of Prenatal Exposure to Two Dietary Chromium Supplements, Chromium Picolinate and [Cr3O(O2CCH2CH3)6(H2O)3] in Mice. Birth Defects Research (Part B) 83:27-31. Berner TO, Murphy MM, Slesinki R. 2004. Determining the safety of chromium tripicolinate. The ENVIRON Health Sciences Institute, Arlington. Food and Chemical Toxicology 42:1029-1042. Beskid M, Jachimowicz J, Taraszewska A, Kukulska D. 1995. Histological and ultra structural changes in the rat brain following systemic administration of picolinic acid. Experimental and Toxicologic Pathology 47(1):25-30. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. 2000. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1alpha and -1beta in macrophages. The Journal of Immunology 164(6):3283-3291. COM 2004: Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment. Statement on the Mutagenicity of Trivalent Chromium and Chromium Picolinate.

December 2004. Department of Health. United Kingdom. [Accessed 2009 December 4]. Available from: http://www.advisorybodies.doh.gov.uk/Com/chromium.htm Coryell V, Stearns D. 2006. Molecular analysis of hprt mutations induced by chromium picolinate in CHO AA8 cells. Mutation Research 610:114-123. CRN 2003: Council for Responsible Nutrition. Chromium Picolinate: Safe at a Wide Range of Intakes. [Accessed 2009 December 4]. Available from: http://www.crnusa.org/pdfs/CRNChromPicBG.pdf Dillon CT, Lay PA, Bonin AM, Cholewa M, Legge GJF. 2000. Permeability, cytotoxicity, and genotoxicity of Cr(III) complexes and some Cr(V) analogues in V79 Chinese hamster lung cells. Chemical Research in

Toxicology 13(8):742-748. ENVIRON 2002: ENVIRON International Corporation. 2002. Generally Recognized as Safe (GRAS) Determination for the User of Chromax Chromium Picolinate as a Nutrient Supplement in Food. Arlington(VA). EPA 1998: U.S. Environmental Protection Agency. 1998. Toxicological Review of Trivalent Chromium: In support of summary information on the Integrated Risk Information System (IRIS). Washington (DC). Evans GW, Bowman TD. 1992. Chromium picolinate increases membrane fluidity and rate of insulin internalization. Journal of Inorganic Biochemistry 46(4):243-250 Evans GW, Johnson PE. 1980.

Characterization and quantitation of a zinc-binding ligand in human milk. Pediatric Research 14(7):876-880. Fernandez-Pol JA. 1978. Morphological changes induced by picolinic acid in cultured mammalian cells. Experimental and Molecular Pathology 29(3):348-357. Fowler JF. 2000. Systemic contact dermatitis caused by oral chromium picolinate. Cutis 65(2):116. FSA 2004: Food Standards Agency. United Kingdom. Agency revises chromium picolinate advice Monday 13 December 2004. [Accessed 2009 December 4].

Available from: http://www.food.gov.uk/news/newsarchive/2004/dec/chromiumupdate Gammelgaard B, Jensen K, Steffansen B. 1999. In vitro metabolism and permeation studies in rat jejunum: organic chromium compared to inorganic chromium. Journal of Trace Elements in Medicine and Biology 13(1-2):82-88. Gargas ML, Norton RL, Paustenbach DJ, Finley BL. 1994. Urinary excretion of chromium by humans following ingestion of chromium picolinate: implications for biomonitoring. Drug Metabolism and Disposition 22(4):522-529. Goda K, Kishimoto R, Shimizu S, Hamane Y, Ueda M. 1996. Quinolinic acid and active oxygens: possible contribution of active oxygens during cell death in the brain. Advances in Experimental Medicine and Biology 398:247-254. Goodwin FK, Sack RL. 1974. Behavioral effects of new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man. Journal of Psychiatric Research 11:211-217. Greenberg D, Komorowski JR, Loveday K. 1999. Rat chromosomes are unharmed by orally administered chromium picolinate. Journal of the American College of Nutrition.18:527. Gudi R, Slesinski RS, Clarke JJ, San RHC. 2005. Chromium picolinate does not produce chromosome damage in CHO cells. Mutation Research 587(1-2):140-146. Guidi R, Rao M. 2004. In vitro Mammalian Chromosome Aberration Test. Bioreliance Report no AA85MC.331.BTL HC

1996: Health Canada. Drugs Directorate Labelling Standard: Mineral Supplements. Ottawa (ON): Health Canada. HC 2007: Health Canada. Monograph- Chromium. [Accessed 2009-December 4]. Available from: http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=46&lang=eng HC 2007: Health Canada. Monograph- Multi-vitamin/mineral Supplement. [Accessed 2009 December 4]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodnatur/multivit_min_mono-eng.pdf HC 2009: Health Canada. Licensed Natural Health Products Database. [Accessed 2009 December 4]. Available from: http://webprod.hc-sc.gc.ca/lnhpd-bdpsnh/start-debuter.do?lang=eng Hepburn DD, Burney JM, Woski S, Vincent JB. 2003. The Nutritional Supplement Chromium Picolinate Generates Oxidative DNA Damage and Peroxidised Lipids In Vivo. Polyhedron 22:455-463. Hepburn DD, Vincent JB. 2002.

In vivo distribution of chromium from chromium picolinate in rats and implications for the safety of the dietary supplement. Chemical Research in Toxicology 15(2):93-100. Hepburn DD, Xiao J, Bindom S, Vincent JB, O'Donell J. 2003. Nutritional Supplement Chromium Picolinate Causes Sterility and Lethal Mutations in Drosophilia melangoster. PNAS 100:3766-3771. Hininger I, Benaraba R, Osman M, Faure H, Roussel AM, Anderson RA. 2007. Safety of trivalent chromium complexes: No evidence for DNA damage in human HaCaT keratinocytes. Free Radical Biology & Medicine 42:1759-1765. Huszonek J. 1993. Over-the-counter chromium picolinate. The American Journal of Psychiatry. 150(10):1560-1561. IRIS 1998: Integrated Risk Information System. Toxicological Review of Trivalent Chromium. In Support of Summary Information on the Integrated Risk Information System. [Accessed 2009 December

4]. Available from: http://www.epa.gov/ncea/iris/toxreviews/0028-tr.pdf IRIS 2008: Integrated Risk Information System. Chromium. Washington(DC): U.S. Environmental Protection Agency. [Accessed 2009 December 4]. Available from: http://www.epa.gov/iris/subst/index.html. Ivankovic S, Preussmann R. 1975. Absence of toxic and carcinogenic effects after administration of high doses of chromic oxide pigment in subacute and long term feeding experiments in rats. Food and Cosmetic Toxicology 13:347-351. Jovanovic L, Gutierrez M, Peterson CM. 1999. Chromium supplementation for women with gestational diabetes mellitus. The Journal of Trace Elements in Experimental Medicine 12(2):91-97. Kerger BD, Paustenbach DJ, Corbett GE, Finley BL. 1996.

Absorption and elimination of trivalent and hexavalent chromium in humans following ingestion of a bolus dose of drinking water. Toxicology and Applied Pharmacology 141(1):145-158. Lawrence ME, Kirby DF. 2002. Nutrition and sports supplements: fact or fiction. Journal of Clinical Gastroenterology 35(4):299-306. Lindemann MD, Carter SD, Chiba LI, Dove CR, Lemieux FM, Soutern LI. 2004. A regional evaluation of chromium tripicolinate supplementation of diets fed to reproducing sows. Journal of Animal Science 82:2972-2977. Mackenzie RD, Byerrum RU, Decker CF, Hoppert CA, Langham RF. 1958. Chronic toxicity studies II. Hexavalent and trivalent chromium administered in drinking water to rats.

American Medical Association Archives of Industrial Health 18:232-234. Martin WR, Fuller RE. 1998. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy 18(4):860-862. McLeod MN, Gaynes BN, Golden RN. 1999. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients.

The Journal of Clinical Psychiatry 60(4):237-240. Mehler AH. 1956. Formation of picolinic and quinolinic acids following enzymatic oxidation of 3-hydroxyanthranilic acid. The Journal of Biological Chemistry 218(1):241-254. Melillo G, Bosco MC, Musso T, Varesio L. 1996. Immunobiology of picolinic acid. Advances in Experimental Medicine and Biology 398:135-141. Mita Y, Ishihara K, Yoshiko F, Fukuya Y, Yasumoto K. 2004. Supplementation with Chromium Picolinate Recovers Renal Cr Concentration and Improves Carbohydrate Metabolism and Renal Function in Type 2 Diabetic Mice. Biological Trace Element Research 105:229-248. Morris GS, Guidry KA, Hegsted M, Hasten DL. 1995. Effects of dietary chromium supplementation on cardiac mass, metabolic enzymes, and contractile proteins. Nutrition Research 15(7):1045-1052. NIH 2005: National Institute of Health. Office of Dietary Supplements. 2005. Dietary Supplement Fact Sheet Chromium. [Accessed 2009 December 4]. Available from: http://ods.od.nih.gov/factsheets/chromium_pf.asph2 NTP 1998: National Toxicology Program. 1998. Executive Summary Chromium Picolinate.

[Accessed 2009 December 4]. Available from: http://ntp.niehs.nih.gov/go/15342 NTP 2009: National Toxicology Program. 2009. Testing Status of Agents at NTP. Chromium picolinate monohydrate. [Accessed on 2009 December 4]. Available from: http://ntp.niehs.nih.gov/?objectid=BD466797-123F-7908-7B4627379E1CE3E6 NTP 2009: National Toxicology Program. 2009.

Testing Status of Agents at NTP. Chromium picolinate. [Accessed on 2009 December 4]. Available from: http://ntp.niehs.nih.gov/index.cfm?objectid=BDC7BBDC-123F-7908-7BD2C6D0172F0FB1 NTP 2009: National Toxicology Program. Database Search Application. 2009. Studies with Chromium Picolinate and Chromium Picolinate Monohydrate. [Accessed 2009 December 4]. Available from: http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=chromium%20picolinate&crumbspot=1 Press R, Geller J, Evan G. 1990.

The Effect of Chromium on Serum Cholesterol and Apolipoprotein Fractions in Human Studies. The Western Journal of Medicine.152:41-45. Reading SA, Wecker L. 1996. Chromium picolinate. The Journal of the Florida Medical Association 83(1):29-31. Rhodes MC, Hébert CD, Herbert RA, Morinello EJ, Roycroft JH, Travlos GS, Abdo KM. 2005.

Absence of toxic effects in F344/N rats and B6C3F1 mice following subchronic administration of chronic administration of chromium picolinate monohydrate. Food and Chemical Toxicology 43:21-29. Roth P, Kirchgessner M. 1985. Utilization of Zinc from Picolinic or Citric Acid Complexes in Relation to Dietary Protein Source in Rats. Journal of Nutrition 115:1641-1649. San RH, Clarke JJ. 2004. In vitro Mammalian Cell Gene Mutation (CHO/HGPRT) Test with 48-hour exposure. Bioreliance Report no AA85MC.782048.BTL San RH, Clarke JJ. 2004a.

In vitro Mammalian Cell Gene Mutation (CHO/HGPRT) Test with an Independent Repeat Assay. Bioreliance Report no AA85MC.782001.BTL. SCF/EFSA 2006: Scientific Committee on Food/ European Food Safety Authority. 2006. Tolerable Upper Intake Levels for Vitamins and Minerals by the Scientific Panel on Dietetic products, Nutrition and Allergies (NDA) and Scientific Committee on Food (SCF). Edited by EFSA, Parma, February 2006. Schroeder HA, Balassa JJ, Vinton Jr WH. 1965. Chromium cadmium and lead in rats: effects on lifespan, tumors and tissue levels. Journal of Nutrition 86:51-66. Slesinski RS, Clarke JJ, San RHC, Gudi R. 2005. Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells. Mutatation Research 585(1-2):86-95. Speetjens JK, Collins RA, Vincent JB, Woski SA. 1999.

The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chemical Research in Toxicology 12(6):483-487. Speetjens JK, Parand A, Crowder MW, Vincent JB, Woski SA. 1999. Low-molecular-weight chromium-binding substance and biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ do not cleave DNA under physiologically-relevant conditions. Polyhedron 18(20):2617-2624. Stearns DM, Belbruno JJ, Wetterhahn KE. 1995. A prediction of chromium(III) accumulation in humans from chromium dietary supplements.

The FASEB Journal 9(15):1650-1657. Stearns DM, Silveira SM, Wolf KK, Luke AM. 2002. Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. Mutation Research 513(1-2):135-142. Stout MD, Nyska A, Collins BJ, Witt KL, Kissling GE, Malarkey DE, Hooth MJ. 2009. Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C351 mice for 2 years. National Toxicology Program. Food and Chemical Toxicology 47: 729-733. Tan GY, Zheng SS, Zhang MH, Feng JH, Xie P, Bi JM. 2008. Study of Oxidative Damage in Growing-Finishing Pigs with Continuous Excess Dietary Chromium Picolinate Intake. Biological Trace Element Research 126(1-3):129-40. TGA 1990: Therapeutic Goods Administration. 1990. Therapeutic Goods Regulations. Canberra (AU): Office of Legislative Drafting and Publishing, Attorney-General's Department, SR 1990 No. 394.

[Accessed 2009 December 4]. Available from: http://www.comlaw.gov.au/ComLaw/Legislation/LegislativeInstrumentCompilation1.nsf/framelodgmentattachments/1D614DC409BA903BCA2575F4000F1E38 TGA 2003: Therapeutic Goods Administration. 2003. CMEC Meeting 41 Complementary Medicines Evaluation Committee: Extracted ratified minutes forty-first meeting. Symonston (AU): Commonwealth Department of Health and Ageing, Therapeutic Goods Administration. [Accessed 2009 December 4]. Available from: http://www.tga.gov.au/docs/pdf/cmec/cmecmi41.pdf. Vincent JB. 2000. The biochemistry of chromium.

The Journal of Nutrition 130(4):715-718. Wang Y, Jones PJ. 2004. Conjugated linoleic acid and obesity control: efficacy and mechanisms. International Journal of Obesity and Related Metabolic Disorders 28(8):941-955. Whittaker P, San RHC, Clarke JJ, Seifried HE, Dunkel VC. 2005. Mutagenicity of chromium picolinate and its components in Salmonella typhimurium and L5178Y mouse lymphoma cells. Food and Chemical Toxicology 43(11):1619-1625. WHO 1996: World Health Organization. 1996. Trace elements in human nutrition and health (A report of a re-evaluation of the role of trace elements in human health and nutrition). Geneva (CH): World Health Organization WHO 1997: World Health Organization. 1997. International Agency for Research on Cancer (IARC), Volume 49: Chromium, nickel and Welding. [online]. Geneva (CH): IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, World Health Organization.

[Accessed 2009 December 4]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol49/volume49.pdf WHO 2009: World Health Organization. 2009. Concise International Chemical Assessment Document 76. Inorganic Chromium (III) Compounds. Geneva (CH): World Health Organization Witmer C, Faria E, Park H, Sadrieh N, Yurkow E, O'Connell S, Sirak A, Schleyer H. 1994. In vivo effects of chromium. Environmental Health Perspectives 102(Supplement 3):169-176. Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Takino T, Sakurai H, Kojima Y. 2002. Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization,in vitro, and in vivo studies, Journal of Biological Inorganic Chemistry 7:68-73. Young PC, Turiansky GW, Bonner MW, Benson PM. 1999. Acute generalized exanthematous pustulosis induced by chromium picolinate. Journal of the American Academy of Dermatology 41(5 Part 2):820-823

 

Add To FavoritesClick Here: To Add This Page To Your Favorites

Nutriteck Dietary Supplement Manufacturers Ingredients Private Label Bulk Pre Filled Capsules

Equine Horse Care Supplements

 

Nutriteck Order Desk Toll Free Numbers

Information provided on this site is for educational use only, and is not intended as medical advice. If you have any serious health concerns you should always check with your health care practitioner before self-administering remedies. This information has not been evaluated by the US Food and Drug Administration. These products are not intended to treat, cure or diagnose any medical condition.

Revision Date: 04/15/2018 ©Copyright Ultra Bio-Logics Inc. International - All Rights Reserved